Vivos Therapeutics (VVOS) EBIAT (2020 - 2025)
Historic EBIAT for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$5.4 million.
- Vivos Therapeutics' EBIAT fell 10642.2% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.1 million, marking a year-over-year decrease of 3579.46%. This contributed to the annual value of -$11.1 million for FY2024, which is 1811.76% up from last year.
- Per Vivos Therapeutics' latest filing, its EBIAT stood at -$5.4 million for Q3 2025, which was down 10642.2% from -$5.0 million recorded in Q2 2025.
- Vivos Therapeutics' 5-year EBIAT high stood at -$1.7 million for Q1 2023, and its period low was -$7.4 million during Q4 2021.
- Its 5-year average for EBIAT is -$4.4 million, with a median of -$4.3 million in 2023.
- Per our database at Business Quant, Vivos Therapeutics' EBIAT crashed by 20074.43% in 2021 and then soared by 6805.48% in 2023.
- Quarter analysis of 5 years shows Vivos Therapeutics' EBIAT stood at -$7.4 million in 2021, then increased by 18.18% to -$6.0 million in 2022, then grew by 29.26% to -$4.3 million in 2023, then surged by 33.89% to -$2.8 million in 2024, then crashed by 91.02% to -$5.4 million in 2025.
- Its EBIAT stands at -$5.4 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$3.9 million for Q1 2025.